Antibodies against IL‐17A or IL‐17 receptor are approved for the treatment of psoriasis [56] and are currently being evaluated for treatment of inflammatory diseases [57] and different cancers [58, 59, 60] and should also be considered for cervical cancer therapy, potentially in combination with chemoradiotherapy. Here, IL17A is linked to psoriasis.